2023 Targeted Therapies of Lung Cancer Meeting

Welcome Message

Fact: As of 2020, the #lungcancer survival rate increased 14.5% over the last five years nationally to 23.7%, yet remains significantly lower among communities of color at 20.0%, and Black Americans at 18.0%. #LCAM22 #LCSM

This guideline reflects a new staging system for people with #thymoma and #thymiccarcinoma which includes recommendations developed to improve management of #thymic epithelial tumors in patients.
https://bit.ly/3GDqHXp #LCSM

The #EUCancerPlan introduced new #lungcancer screening recommendations based on the latest technology, scientific developments & evidence in 3 key areas: access, quality, & diagnostics with a focus on increasing the number of earlier diagnoses. https://bit.ly/3ghtnip #LCAM22

Fact: #Lungcancer screening is an opportunity to save lives. Screening with annual low-dose CT scans can reduce the lung cancer death rate by up to 20% by detecting tumors at early stages, when the cancer is more likely to be curable. #LCAM22 #LCSM

Load More

Dear Colleagues and Friends,  

The IASLC 2023 Targeted Therapies of Lung Cancer Meeting will take place February 22-25, 2023 at the Fairmont Miramar in Santa Monica, California, United States. After two years of virtual meetings, we are thrilled to invite you to join us again in a face-to-face meeting with virtual elements that will enhance participant’s experience and allow anyone from anywhere to join this unique meeting.  

The IASLC Targeted Therapies of Lung Cancer Meeting is a dynamic meeting with a long tradition. Meeting presenters will summarize the data on relevant targets for new therapies and share data on preclinical and early clinical data for each of the drugs directed against these targets. 

We can’t wait to see you again in Santa Monica in February 2023.

TTLC 2023 Meeting Chairs

Paul A Bunn

Paul A. Bunn, Jr.
MD

Charu Aggarwal

Charu Aggarwal
MD

Lecia Sequist

Lecia Sequist
MD

Joel Neal

Joel Neal
MD, PhD